Managing opioid-induced constipation in advanced illness: Focus on methylnaltrexone bromide

Therapeutics and Clinical Risk Management

Volumn 6, Issue 1, 2010, Pages 77-82

  Clemens, Katri Elina ^a,b   Klaschik, Eberhard ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Malteser Hospital Bonn/Rhein Sieg   (Germany)

Author keywords

Methylnaltrexone bromide; Opioid induced constipation; Opioids; Palliative care

Indexed keywords

17 METHYLNALTREXONE BROMIDE; LAXATIVE; OPIATE; OPIATE ANTAGONIST; PLACEBO; PROKINETIC AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; CONSTIPATION; DEFECATION URGENCY; DISEASE SEVERITY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TOLERABILITY; FLATULENCE; HUMAN; INTESTINE CONTRACTION; INTESTINE FUNCTION; INTESTINE TRANSIT TIME; LIQUID FECES; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPIOID INDUCED CONSTIPATION; PALLIATIVE THERAPY; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; STOMACH EMPTYING; WITHDRAWAL SYNDROME;

EID: 77950839201     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s4301     Document Type: Review

References (49)

1. Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer. 1998;6:356-364.
2. Vainio A, Auvinen A. Prevalence of symptoms among patients with advanced cancer: an international collaborative study. J Pain Symptom Manage. 1996;12:3-10.
3. Fallon MT. Constipation in cancer patients: prevalence, pathogenesis, and cost-related issues. Eur J Pain. 1999;3(suppl):3-7.
4. Goodman ML, Wilkinson S: Laxatives for the management of constipation in palliative care patients. The Cochrane Library. 2004;1-11.
5. Bruera E, Suarez-Almazor M, Velasco A, et al. The assessment of constipation in terminal cancer patients admitted to a palliative care unit: a retrospective review. J Pain Symptom Manage. 1994;9:515-519.
6. Goodman M, Low J, Wilkinson S. Constipation management in palliative care: a survey of practices in the United Kingdom. J Pain Symptom Manage. 2005;29:238-244.
7. Larkin PJ, Sykes NP, Centeno C, et al; European Consensus Group on Constipation in Palliative Care. The management of constipation in palliative care: clinical practice recommendations. Palliat Med. 2008;22:796-807.
8. Mancini I, Bruera E. Constipation. In: Ripamonti C, Bruera E, eds. Gastrointestinal Symptoms in Advanced Cancer Patients. New York: Oxford University Press; 2002:193-206.
9. Chang L. From Rome to Los Angeles The Rome III Criteria for the Functional GI Disorders. Gastroenterology. 2006;130:1480-1491.
10. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63:649-671.
11. Mikus G. Combining opioid agonists and antagonists as a solution for opioid-induced constipation. European Gastroenterology and Hepatology Review. 2009:71-74.
12. Ramsin B, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11:S105-S120
13. Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage. 2008;35:103-113.
14. Fallon MT, Hanks GW. Morphine, constipation and performance status in advanced cancer patients. Palliat Med. 1999;13:159-160.
15. Stewart WF, Libermann JN, Sandler RS, et al. Epidemiology of constipation (EPOC) Study in the United States: relation of clinical subtypes to socioeconomic features. Am J Gastroenterol. 1999;94:3530-3539.
16. Wanitschke R, Goerg KJ, Loew D. Differential therapy of constipation a review. Int J Clin Pharmacol Ther. 2003;41:14-21.
17. Clemens KE, Klaschik E. Management of constipation in palliative care patients. Curr Opin Support Palliat Care. 2008;2:22-27.
18. Clemens KE, Klaschik E. Managing nausea, emesis and constipation in palliative care. Dtsch Arztebl. 2007;104:269-278.
19. Manara L, Bianchi G, Ferretti P, Tavani A. Inhibitation of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid investigational sites. J Pharmacol Exp Ther. 1986;237:945-949.
20. Tavani A, Bianchi G, Ferretti P, Manara L. Morphine most effective on gastrointestinal propulsion in rats by intraperitoneal route: evidence for local action. Life Sci. 1980;27:2211-2217.
21. Kaufman PN, Krevesky B, Malmud LS, et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology. 1998;94: 1351-1356.
22. Jurna I, Baldauf J. Retardiert freigesetztes Naloxon oral: Aufhebung der Obstipation durch orales Morphin ohne Beseitigung der Analgesie. Der Schmerz. 1993;7:314-21.
23. Meissner W, Schmidt U, Hartmann M, et al. Oral naloxone reverses opioid-associated constipation. Pain. 2000;84:105-109.
24. Shaiova L, Rim F, Friedman D, Jahdi M. A review of methylnaltrexone, a peripheral opioid receptor antagonist, and its role in opioid-induced constipation. Palliate Support Care. 2007;5:161-166.
25. Herndon CM, Jackson KC, Halllin PA. Management of opiodinduced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy. 2002;22:240-250.
26. Becker G, Blum HE. Novel opioid-antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet. 2009;373:1198-1206.
27. Brown DR, Goldberg LI. The use of quaternary narcotic antagonist in opiate research. Neuropharmacology. 1985;24:181-192.
28. Yuan CS, Foss JF. Methylnaltrexone: investigation of clinical applications. Drug Dev Res. 2000;50:133-141.
29. DeHaven-Hudkins DL, DeHaven RN, Little PJ, Techner LM. The involvement of the opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor. Pharmaco Ther. 2008;117:162-187.
30. Yuan CS, Israel RJ. Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opin Investig Drugs. 2006;15:541-552.
31. Reichle FM, Conzen PF. Methylnaltrexone, a new peripheral μ-receptor antagonist for the prevention and treatment of opioid-induced extracerebral side effects. Curr Opin Investig Drugs. 2008;9:90-100.
32. Yuan SC, Doshan H, Charney MR, et al. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol. 2005;45:538-546.
33. Holzer P. New approaches to the treatment of opioid-induced constipation. Eur Rev Medi Pharmacol Sci. 2008;12:119-127.
34. Rosow CE, Gomery P, Chen TY, Stefanovich P, Stambler N, Israel R. Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin Pharmacol Ther. 2007;82:48-53.
35. Murphy DB, Sutton JA, Prescott LF, Murphy MB. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology. 1997;87:765-770.
36. Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, Moss J. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebocontrolled trial. Clin Pharmacol Ther. 1996;59:469-475.
37. Yuan CS, Foss JF, Osinksi J, Toledano A, Roizen MF, Moss J. The safety and efficacy of oral methylnaltrexone in preventing morphineinduced delay in oral-cecal transit-time. Clin Pharmacol Ther. 1997;61: 467-475.
38. Yuan CS, Wei G, Foss JF, O'Connor M, Karrison T, Osinski J. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side-effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther. 2002;300:118-123.
39. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358:2332-2343.
40. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA. 2000;283:367-372.
41. Yuan CS, Foss FJ. Oral methylnaltrexone for opioid-induced constipation. JAMA. 2000;11:1383-1384.
42. Berde C, Nurko S. Opioid side effects mechanism-based therapy. N Engl J Med. 2008;358:2400-2402.
43. Beattie DT, Cheruvu M, Mai N, et al. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011and methylnaltrexone. Naunyn-Schmiedeberg's Arch Pharmacol. 2007;375:205-220.
44. McNicol ED, Boyce D, Schumann R, Carr DB. Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev. 2008;2:CD006332.
45. Herbert MK, Holzer P. Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients current status and future options. Clin Nutr. 2008;27:25-41.
46. Yuan CS, Foss JF, O'Connor M, Osinksi J, Roizen MF, Moss J. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. J Pain. 1999;83:631-635.
47. Neary P, Delaney CP. Alvimopan. Expert Opin Investig Drugs. 2005; 14:479-488.
48. Kotake AN, Kuwahara SK, Burton E, McCoy CE, Goldberg LI. Variations in demethylation of N-methylnaterxone in mice, rats, dog, and humans. Xenobiotica 1989;19:1247-1254.
49. European Medicines Agency (EMEA). URL: http://www.emea.europa.eu/, accessed 19 September 2009.